What we do

What we do

AriBioLab Co., Ltd. is a biotechnology company developing vaccine-based technologies related to neurodegenerative diseases, building on its research and development capabilities in the field of degenerative brain diseases.

Through R&D focused on the multiple mechanisms underlying degenerative brain diseases, AriBioLab has secured differentiated technological expertise and aims to present new therapeutic strategies through vaccine-based approaches.

AriBioLab Co., Ltd. is committed to advancing its research and technologies to become a globally competitive biotechnology company in the field of degenerative brain disease treatment.

• Company Name AriBioLab Co.,Ltd.
• Operated Since April. 2026 (Company name changed in 2026)
• CEO Jai Jun Choung (Research Division)
  Soo-Hyun Sung (Management Division)
• Core Technology Novel Vaccine Adjuvant (L-pampo): HBV, Influenza, VZV, TB vaccines, Cancer therapeutic vaccines & more Recombinant Antigen development: 3rd generation HBV antigen L-HBsAg (S+preS), HBcAg, VZV gE antigen, Cancer antigen CT45 etc Development of Flu Medicines: MBL (Mannose Binding Lectin)
• Corp. Office HQ: Seongnam, Korea